Introducing thymus for promoting transplantation tolerance - 05/09/22

Abstract |
Establishing tolerance remains a central, if elusive, goal of transplantation. In solid-organ transplantation, one strategy for inducing tolerance has been cotransplantation of various forms of thymic tissue along with another organ. As one of the biological foundations of central tolerance, thymic tissue carries with it the ability to induce tolerance to any other organ or tissue from the same donor (or another donor tissue-matched to the thymic tissue) if successfully transplanted. In this review, we outline the history of this approach as well as work to date on its application in organ transplantation, concluding with future directions. We also review our experience with allogeneic processed thymus tissue for the treatment of congenital athymia, encompassing complete DiGeorge syndrome and other rare genetic disorders, and consider whether allogeneic processed thymic tissue implantation may offer a novel method for future experimentation with tolerance induction in organ transplantation.
Le texte complet de cet article est disponible en PDF.Key words : Thymus transplantation, tolerance, DiGeorge syndrome, organ transplantation, T cells
Abbreviations used : CTT, CTTI, cGvHD, TCR, TEC, TLI, TSA, VTL
Plan
| Disclosure of potential conflict of interest: J. Kwun, M. L. Markert, and J. W. Turek received research funding from Enzyvant Therapeutics GmbH. M. L. Markert developed the technology of allogeneic processed thymus tissue (cultured thymus tissue) for implantation, which now is a Food and Drug Administration–approved product, and has received royalties from Enzyvant. If the technology is commercially successful in the future, M. L. Markert and Duke may benefit financially. J. Kwun and S. J. Knechtle received research funding from Alexion, eGenesis, and MorphoSys. S. J. Knechtle is a consultant to Norvartis, Visterra, and Hansa Biopharma. A. D. Kirk has served as a consultant for AskBio, CareDx, Novartis, Sanofi, Transplant Genomics, Veloxis, and Vertex; has received grant support from Bristol Myers Squibb; and serves on the Board of Directors for Clinetic. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 150 - N° 3
P. 549-556 - septembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
